Sensei Biotherapeutics, Inc. financial data

Symbol
SNSE on Nasdaq
Location
1405 Research Blvd, Suite 125, Rockville, MD
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 700 % -35.8%
Debt-to-equity 18.5 % +24.8%
Return On Equity -80 % -48.6%
Return On Assets -67.5 % -43.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.26M shares -95%
Common Stock, Shares, Outstanding 1.26M shares -95%
Entity Public Float 10.3M USD -44.9%
Common Stock, Value, Issued 0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 1.26M shares +0.32%
Weighted Average Number of Shares Outstanding, Diluted 1.26M shares +0.32%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 11.4M USD -17.9%
Operating Income (Loss) -25.6M USD +21.2%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -24.1M USD +19%
Earnings Per Share, Basic 2 USD/shares +37.3%
Earnings Per Share, Diluted 2 USD/shares +37.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 10.6M USD -44.8%
Other Assets, Current 248K USD +206%
Assets, Current 25.8M USD -46.4%
Property, Plant and Equipment, Net 112K USD -87.5%
Operating Lease, Right-of-Use Asset 1.67M USD -48%
Other Assets, Noncurrent 18K USD -79.3%
Assets 27.6M USD -48.2%
Accounts Payable, Current 306K USD
Employee-related Liabilities, Current 1.16M USD -13.1%
Accrued Liabilities, Current 1.02M USD
Liabilities, Current 4.44M USD -18.5%
Operating Lease, Liability, Noncurrent 146K USD -92%
Other Liabilities, Noncurrent 67K USD -6.94%
Liabilities 4.58M USD -38.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -3K USD -121%
Retained Earnings (Accumulated Deficit) -278M USD -9.49%
Stockholders' Equity Attributable to Parent 23M USD -49.7%
Liabilities and Equity 27.6M USD -48.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.09M USD +6.85%
Net Cash Provided by (Used in) Financing Activities -214K USD -2.39%
Net Cash Provided by (Used in) Investing Activities 7.19M USD +24.6%
Common Stock, Shares Authorized 12.5M shares -95%
Common Stock, Shares, Issued 1.26M shares -95%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -117K USD +94.3%
Deferred Tax Assets, Valuation Allowance 58.2M USD +14%
Deferred Tax Assets, Gross 59M USD +12.1%
Operating Lease, Liability 1.83M USD -46.7%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -24.2M USD +17.8%
Lessee, Operating Lease, Liability, to be Paid 1.9M USD -48.6%
Property, Plant and Equipment, Gross 622K USD -79.5%
Operating Lease, Liability, Current 1.68M USD +4.93%
Lessee, Operating Lease, Liability, to be Paid, Year Two 59K USD -95.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.41M USD -19.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 72K USD -72.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 59K USD -95.8%
Deferred Tax Assets, Operating Loss Carryforwards 37M USD +11.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 59K USD -95.8%
Operating Lease, Payments 476K USD +3.03%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 444K USD -18.8%
Deferred Tax Assets, Net of Valuation Allowance 848K USD -47.8%
Share-based Payment Arrangement, Expense 1.37M USD -64.3%
Interest Expense 46K USD -55.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%